ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,306.04
0.00%
Dow Jones
38,852.86
0.00%
US Dollar vs MXN
16.87168
0.45%
Brent Oil
84.275
-0.06%
Bitcoin
67,679.60
-0.89%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CNS Pharmaceuticals Inc (CNSP)

  7. CNS Pharmaceuticals Inc (CNSP) Noticias

CNSP

CNS Pharmaceuticals (CNSP)

CNS Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CNSP
FechaHoraFuenteTítuloSímboloCompañía
19/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNSPCNS Pharmaceuticals Inc
16/05/202409:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202416:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202416:28Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
06/02/202409:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
06/02/202409:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
31/01/202415:27Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CNSPCNS Pharmaceuticals Inc
22/01/202405:02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
08/12/202316:28Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
30/11/202316:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNSPCNS Pharmaceuticals Inc
12/10/202317:01Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
14/08/202316:12Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202307:40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202307:39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202316:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNSPCNS Pharmaceuticals Inc
01/05/202318:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNSPCNS Pharmaceuticals Inc
31/03/202316:05Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
29/03/202308:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight EventNASDAQ:CNSPCNS Pharmaceuticals Inc
13/03/202306:05PR Newswire (US)CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank IssuesNASDAQ:CNSPCNS Pharmaceuticals Inc
09/03/202308:05PR Newswire (US)CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandNASDAQ:CNSPCNS Pharmaceuticals Inc
14/02/202311:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNSPCNS Pharmaceuticals Inc
07/02/202307:45PR Newswire (US)CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMNASDAQ:CNSPCNS Pharmaceuticals Inc
12/01/202307:45PR Newswire (US)CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandNASDAQ:CNSPCNS Pharmaceuticals Inc
05/01/202308:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:CNSPCNS Pharmaceuticals Inc
03/01/202311:00PR Newswire (US)CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of DirectorsNASDAQ:CNSPCNS Pharmaceuticals Inc
08/12/202208:08PR Newswire (US)CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)NASDAQ:CNSPCNS Pharmaceuticals Inc
05/12/202207:05PR Newswire (US)CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" EventNASDAQ:CNSPCNS Pharmaceuticals Inc
05/12/202205:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:CNSPCNS Pharmaceuticals Inc
01/12/202205:12Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CNSPCNS Pharmaceuticals Inc
30/11/202221:00PR Newswire (US)CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing PriceNASDAQ:CNSPCNS Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CNSP

Su Consulta Reciente

LSE
61SO
Sg Issuer23
EU
CAP
Capgemini
DGFX
SYMUSDT
SymVerse
USOTC
CAVVF
Cavu Energy Metals (PK)
LSE
FM48
Mitsu Hc Cap.24
ASX
ART
Airtasker
NASDAQ
CFSSX
Column Small Cap Select
TG
XBEE
Xtrackers Europe Biodive...
COIN
FLOKIKRW
FLOKI
ASX
AHGKOQ
LSE
46TQ
Municplty. 39
ASX
BHPKOJ
TG
6CA
Cartier Res
COIN
WINNNBTC
TG
T1EU
Invesco Markets II
NASDAQ
FLIKDX
Etf Growth and Income Ju...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados